Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948432 | 1.00 | DRD2 (0.35) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL23691473 | 0.86 | SLC6A2 (0.30) | TSHRADRA1A | |
| SCHEMBL16555652 | 0.75 | EPAS1 (0.43) | — | |
| SCHEMBL193673 | 0.74 | DRD2 (0.43) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL193672 | 0.74 | DRD2 (0.43) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL1478094 | 0.74 | POLL (0.32) | — | |
| SCHEMBL10190836 | 0.74 | DRD2 (0.33) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL10244127 | 0.74 | DRD2 (0.38) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL13924869 | 0.74 | DRD2 (0.33) | DRD2DRD3CYP1A2HTR1ACYP2D6 | |
| SCHEMBL19679339 | 0.74 | CYP1A2 (0.38) | DRD2CYP1A2HTR1ACYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2178880-B1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARM INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933225-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885CYP1A2 235/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | DRD2 2265/4885DRD3 3014/4885CYP1A2 575/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | DRD2 2265/4885DRD3 3014/4885CYP1A2 575/4885 |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885CYP1A2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.